FoxHollow Announces New Senior Vice President of Global Sales; Industry Veteran Brings Proven Experience in Leading Sales Initia
28 Février 2007 - 3:00PM
PR Newswire (US)
REDWOOD CITY, Calif., Feb. 28 /PRNewswire/ -- FoxHollow
Technologies, Inc. (NASDAQ:FOXH), which develops and markets
endovascular therapeutic devices for the treatment of peripheral
artery disease (PAD), today announced the hiring of Kevin Cordell
as the company's new Senior Vice President of Global Sales. In his
new role, Mr. Cordell will lead FoxHollow's worldwide sales
organization, focusing and executing on corporate strategies for
the growth and expansion of FoxHollow's current product lines as
well as the expansion of the company's product portfolio with the
integration of potential future product acquisitions. "We are
excited to welcome Kevin Cordell to FoxHollow's senior management
team. Kevin brings to us an incredible depth of sales leadership
experience, which is vital to both the achievement of our revenue
goals and our long-term growth as a market leader in vascular
technologies," noted Duke Rohlen, President of Strategic
Operations. "Kevin has a proven track record of success in the
interventional cardiovascular space, and we are delighted to have
him on FoxHollow's leadership team as we continue to execute on our
recently-outlined corporate strategy," Rohlen continued. Mr.
Cordell joins FoxHollow with over 12 years of experience in the
pharmaceutical, biotech and medical device industries. Most
recently, Mr. Cordell served as Vice President of Sales, from 2005
to the present for Cordis Cardiology, a Johnson & Johnson
Company specializing in medical devices for vascular intervention.
Specifically, over the last four years, he led U.S. sales in the
highly competitive coronary stent market. "I am already impressed
with FoxHollow's strong commitment to helping physicians and
improving patient outcomes, and I am excited to join the company
and continue these efforts," commented Mr. Cordell. "I am very
enthusiastic about the opportunity to work with FoxHollow's
market-leading sales organization as the company launches new
products, advances clinical programs, and broadens the product
portfolio, with the mission of becoming a leading vascular
solutions company," added Cordell. Mr. Cordell joined Cordis
Cardiology in 2003 as Executive Sales Director and was a board
member of the company. Prior to working at Cordis, he held various
sales and marketing positions at Centocor, Inc., a subsidiary of
Johnson & Johnson, focusing on the development of biomedicines
to treat immune disorders. He began his sales career in 1993 at
Boehringer Mannheim Corporation, a wholly-owned subsidiary of the
Roche Corporation. Mr. Cordell holds a Bachelor of Business
Administration from the University of Oklahoma. About FoxHollow
Technologies, Inc. FoxHollow Technologies, Inc. develops and
markets endovascular therapeutic devices for the treatment of
peripheral artery disease (PAD). PAD results from plaque that
accumulates in the arteries and blocks blood flow in the legs.
These blockages can result in severe pain for patients and very
limited physical mobility. The company's SilverHawk(R) Plaque
Excision System is a minimally invasive method of removing
obstructive plaque and restoring blood flow to the legs and feet.
The company's Rinspirator(R) System removes thrombus, or blood
clots, from occluded arteries in patients suffering from PAD or
coronary artery disease (CAD). For more information, please visit
our website at http://www.foxhollowtech.com/ . Forward-Looking
Statements This press release contains forward-looking statements
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995. Statements in this press release regarding FoxHollow's
business that are not historical facts may be "forward-looking
statements" that involve risks and uncertainties. Specifically,
expectations regarding future product releases and acquisitions are
forward-looking statements involving risks and uncertainties.
Forward-looking statements are based on management's current,
preliminary expectations, and are subject to risks and
uncertainties that could cause actual results to differ from the
results predicted and which are included under the caption,
"Factors Affecting Future Operating Results," in "Management's
Discussion and Analysis of Financial Condition and Results of
Operations," in our most recent quarterly report on Form 10-Q for
the quarter ended September 30, 2006 filed with the SEC on November
9, 2006, and available on our investor relations website at
http://investor.foxhollowtech.com/ and on the SEC's website at
http://www.sec.gov/ . Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they
are made. FoxHollow undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date they were made, or to reflect the
occurrence of unanticipated events. Contacts: Matt Ferguson Chief
Financial Officer 650-421-8449 Robin Gaffney Media Relations
650-421-8614 DATASOURCE: FoxHollow Technologies, Inc. CONTACT: Matt
Ferguson, Chief Financial Officer, +1-650-421-8449, or , or Robin
Gaffney, Media Relations, +1-650-421-8614, or , both of FoxHollow
Technologies, Inc. Web site: http://www.foxhollowtech.com/
Copyright
Foxhollow (NASDAQ:FOXH)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Foxhollow (NASDAQ:FOXH)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024